Vaccine development: From preclinical studies to phase 1/2 clinical trials

11Citations
Citations of this article
89Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Vaccines are biological pharmaceutical products prescribed as prevention of a hypothetical infection. Development of a new vaccine is the result of a long process involving several stages. During all developmental phases, priority is the safety of the new product, which is often used in young infants. The initial research phase lasts 1–5 years and is followed by a clinical and pharmaceutical development phase (preclinical and clinical phases), which can last from 15 to 20 years on average before licensure is obtained. There are, however, exceptions, like the malaria vaccine for which research has been going on for more than 30 years and at least 30 candidate vaccines have been assessed. This chapter summarizes the different phases of vaccine candidate development from preclinical studies to phase 2 vaccine trials.

Cite

CITATION STYLE

APA

Artaud, C., Kara, L., & Launay, O. (2019). Vaccine development: From preclinical studies to phase 1/2 clinical trials. In Methods in Molecular Biology (Vol. 2013, pp. 165–176). Humana Press Inc. https://doi.org/10.1007/978-1-4939-9550-9_12

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free